You are here

Nature biotechnology DOI:10.1038/nbt.1513

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Publication TypeJournal Article
Year of Publication2009
AuthorsDu, J, Bernasconi, P, Clauser, KR, Mani, DR, Finn, SP, Beroukhim, R, Burns, M, Julian, B, Peng, XP, Hieronymus, H, Maglathlin, RL, Lewis, TA, Liau, LM, Nghiemphu, P, Mellinghoff, IK, Louis, DN, Loda, M, Carr, SA, Kung, AL, Golub, TR
JournalNature biotechnology
Date Published2009/01/01

The aberrant activation of tyrosine kinases represents an important oncogenic mechanism, and yet the majority of such events remain undiscovered. Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase-activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo. Testing of dasatinib-resistant tyrosine kinase alleles confirmed that SRC is indeed the relevant target of dasatinib, which inhibits many tyrosine kinases. These studies establish the feasibility of tyrosine kinome-wide phosphorylation profiling and point to SRC as a possible therapeutic target in glioblastoma.